Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.

Fiche publication


Date publication

octobre 2018

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Dr GRANEL-BROCARD Florence


Tous les auteurs :
Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, Borget I

Résumé

Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which showed significant improvement in survival. In France, in 2004, the cost of MM was estimated at €1634 per patient; this cost has not been re-estimated since. This study provided an update on survival and cost in real-life clinical practice.

Mots clés

Cost, Immunotherapy, Metastatic melanoma, Real-life clinical practice, Survival, Targeted therapy

Référence

Eur. J. Cancer. 2018 Oct 29;105:33-40